 cardiac toxic year anthracyclin therapi cardiac statu long-term survivor pediatr malign chemotherapi anthracyclin design method.-pati echocardiogram year median year complet anthracyclin prospect retrospect analysi consecut sampl patient total anthracyclin dose median patient mediastin radiotherapi main outcom overal incid sever abnorm systol cardiac function entir cohort risk factor total anthracyclin dose mediastin radiotherapi age treatment length follow-up twenty-thre percent cohort abnorm cardiac function noninvas test long-term follow-up correl total cumul dose length follow-up mediastin irradi incid abnorm signific fifty-six patient year median year median anthracyclin dose thirty-eight percent patient patient year abnorm find sixty-thre percent patient year anthracyclin abnorm find nine patient late symptom cardiac failur dysrhythmia patient microscop examin myocardium biopsi autopsi fibrosi incid late cardiac abnorm warrant evalu patient anthracyclin patient care design futur chemotherapeut protocol